Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATYRNYSE:DNANASDAQ:IOBTNASDAQ:SAGE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATYRAtyr PHARMA$5.14-4.6%$3.40$1.42▼$5.75$479.73M0.88985,501 shs4.68 million shsDNAGinkgo Bioworks$7.56+1.1%$7.24$5.00▼$22.60$437.82M1.251.44 million shs705,224 shsIOBTIO Biotech$1.45-4.0%$1.03$0.66▼$1.73$95.53M0.09279,004 shs192,399 shsSAGESage Therapeutics$6.54+0.2%$7.04$4.62▼$13.47$409.54M0.21.18 million shs534,865 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATYRAtyr PHARMA-4.64%+22.38%+43.58%+66.88%+513,999,900.00%DNAGinkgo Bioworks+1.04%+1.61%+9.33%-3.26%-64.24%IOBTIO Biotech-3.97%+21.85%+27.19%+58.12%+20.83%SAGESage Therapeutics+0.15%+0.93%-8.79%-13.72%-38.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATYRAtyr PHARMA2.8441 of 5 stars3.61.00.00.03.43.30.6DNAGinkgo Bioworks0.8799 of 5 stars0.82.00.00.02.12.51.3IOBTIO Biotech3.6744 of 5 stars3.73.00.00.04.02.51.3SAGESage Therapeutics3.5515 of 5 stars3.01.00.04.01.51.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATYRAtyr PHARMA 3.14Buy$18.60261.87% UpsideDNAGinkgo Bioworks 1.67Reduce$5.77-23.72% DownsideIOBTIO Biotech 3.33Buy$9.33543.68% UpsideSAGESage Therapeutics 2.06Hold$8.8735.58% UpsideCurrent Analyst Ratings BreakdownLatest IOBT, ATYR, DNA, and SAGE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2025ATYRAtyr PHARMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.005/19/2025ATYRAtyr PHARMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00 ➝ $35.005/14/2025IOBTIO BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/25/2025SAGESage TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/1/2025IOBTIO BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/14/2025ATYRAtyr PHARMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00 ➝ $35.003/12/2025IOBTIO BiotechPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/11/2025SAGESage TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform$5.003/5/2025IOBTIO BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATYRAtyr PHARMA$235K1,946.73N/AN/A$1.54 per share3.34DNAGinkgo Bioworks$237.42M1.86N/AN/A$21.93 per share0.34IOBTIO BiotechN/AN/AN/AN/A$2.02 per shareN/ASAGESage Therapeutics$47.40M8.64N/AN/A$7.56 per share0.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATYRAtyr PHARMA-$50.39M-$0.81N/AN/AN/AN/A-79.44%-59.16%8/12/2025 (Estimated)DNAGinkgo Bioworks-$892.87M-$9.16N/AN/AN/A-298.78%-58.54%-34.24%8/14/2025 (Estimated)IOBTIO Biotech-$86.08M-$1.37N/AN/AN/AN/A-86.56%-75.24%8/12/2025 (Estimated)SAGESage Therapeutics-$400.67M-$5.80N/AN/AN/A-971.50%-68.18%-60.84%7/30/2025 (Estimated)Latest IOBT, ATYR, DNA, and SAGE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025ATYRAtyr PHARMA-$0.19-$0.17+$0.02-$0.17N/AN/A5/6/2025Q1 2025DNAGinkgo Bioworks-$1.23-$1.58-$0.35-$1.68$38.70 million$48.32 million4/29/2025Q1 2025SAGESage Therapeutics-$0.99-$1.01-$0.02-$1.01$14.12 million$14.06 million3/13/2025Q4 2024ATYRAtyr PHARMA-$0.23-$0.18+$0.05-$0.18$0.02 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATYRAtyr PHARMAN/AN/AN/AN/AN/ADNAGinkgo BioworksN/AN/AN/AN/AN/AIOBTIO BiotechN/AN/AN/AN/AN/ASAGESage TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATYRAtyr PHARMA0.025.415.41DNAGinkgo BioworksN/A5.795.79IOBTIO BiotechN/A5.375.37SAGESage TherapeuticsN/A7.427.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATYRAtyr PHARMA61.72%DNAGinkgo Bioworks78.63%IOBTIO Biotech54.76%SAGESage Therapeutics99.22%Insider OwnershipCompanyInsider OwnershipATYRAtyr PHARMA3.70%DNAGinkgo Bioworks9.72%IOBTIO Biotech4.80%SAGESage Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATYRAtyr PHARMA5389.00 million80.84 millionOptionableDNAGinkgo Bioworks64058.53 million51.89 millionOptionableIOBTIO Biotech3065.88 million64.37 millionNot OptionableSAGESage Therapeutics69062.62 million58.10 millionOptionableIOBT, ATYR, DNA, and SAGE HeadlinesRecent News About These CompaniesMajor Depressive Disorder Pipeline Appears Robust With 75+ Key Companies Actively Working in the Therapeutics Segment | DelveInsightJune 5 at 6:04 AM | theglobeandmail.comBank of America Corp DE Sells 355,277 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)June 4 at 3:24 AM | marketbeat.comAmeriprise Financial Inc. Trims Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE)June 4 at 3:03 AM | marketbeat.comBronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach OutJune 3 at 10:00 AM | accessnewswire.comSage Therapeutics (NASDAQ:SAGE) Upgraded at Wall Street ZenJune 2 at 2:41 AM | americanbankingnews.comBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the InvestigationJune 1, 2025 | accessnewswire.comToronto Dominion Bank Makes New $742,000 Investment in Sage Therapeutics, Inc. (NASDAQ:SAGE)June 1, 2025 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Stock Rating Upgraded by Wall Street ZenJune 1, 2025 | marketbeat.comVoloridge Investment Management LLC Cuts Stock Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)May 31, 2025 | marketbeat.comWhy Is Sage Therapeutics (SAGE) Down 11.1% Since Last Earnings Report?May 29, 2025 | zacks.comBronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Stockholders to Inquire about Securities InvestigationMay 29, 2025 | accessnewswire.comMan Group plc Takes Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)May 28, 2025 | marketbeat.comBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Investors to Learn More About the InvestigationMay 27, 2025 | accessnewswire.com136,723 Shares in Sage Therapeutics, Inc. (NASDAQ:SAGE) Purchased by Toronto Dominion BankMay 27, 2025 | marketbeat.comSage Therapeutics, Inc. (NASDAQ:SAGE) Shares Purchased by Millennium Management LLCMay 27, 2025 | marketbeat.comSage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the InvestigationMay 25, 2025 | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Investors to ConnectMay 22, 2025 | accessnewswire.comLazard Asset Management LLC Buys New Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE)May 22, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Buys 114,173 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)May 21, 2025 | marketbeat.comBronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Stockholders to Inquire about Securities InvestigationMay 20, 2025 | accessnewswire.comNeuromodulation: rewiring healthcare?May 19, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIOBT, ATYR, DNA, and SAGE Company DescriptionsAtyr PHARMA NASDAQ:ATYR$5.14 -0.25 (-4.64%) As of 06/4/2025 04:00 PM EasternaTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.Ginkgo Bioworks NYSE:DNA$7.56 +0.08 (+1.07%) As of 06/4/2025 03:58 PM EasternGinkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.IO Biotech NASDAQ:IOBT$1.45 -0.06 (-3.97%) As of 06/4/2025 04:00 PM EasternIO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.Sage Therapeutics NASDAQ:SAGE$6.54 +0.01 (+0.15%) As of 06/4/2025 04:00 PM EasternSage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Robinhood Stock Keeps Giving Investors Reasons To Buy CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast Guidewire Rockets Higher: A Move Above $300 Is Probable TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Intuit's AI Boom: Stock Soaring, But Should Investors Hit Pause? Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Analog Devices' Cyclical Recovery Story Has Just Begun Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
